Search

Author/Creator Badagliacca, R

1. Determinants of pulmonary vascular resistance reduction with upfront oral therapy in idiopathic pulmonary arterial hypertension: relevance in risk assessment. (25th November 2020)

Authors:
Badagliacca, R; D'Alto, M; Ghio, S; Greco, A; Papa, S; Romeo, E; Casu, G; Corda, M; Paciocco, P; D'Agostino, C; Galgano, G; Stolfo, D; Correale, M; Naeije, R; Vizza, C.D
Journal:
European heart journal
Issue:
Volume 41:(2020)Supplement 2
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Long term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): safety, tolerability, clinical, and haemodynamic effect. Issue 5 (29th November 2006)

Authors:
D'Alto, M; Vizza, C D; Romeo, E; Badagliacca, R; Santoro, G; Poscia, R; Sarubbi, B; Mancone, M; Argiento, P; Ferrante, F; Russo, M G; Fedele, F; Calabrò, R
Journal:
Heart
Issue:
Volume 93:Issue 5(2007)
Page Start:
621
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗